A closely watched Alzheimer's drug from Eli Lilly won the backing of federal health advisers on Monday, setting the stage for the treatment's expected approval for people with mild dementia caused by the brain-robbing disease.
Food and Drug Administration advisers voted unanimously that the drug's ability to modestly slow the disease outweighs its risks, including side effects like brain swelling and bleeding that will have to be monitored.
